Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

453 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy.
Pöttgen C, Levegrün S, Theegarten D, Marnitz S, Grehl S, Pink R, Eberhardt W, Stamatis G, Gauler T, Antoch G, Bockisch A, Stuschke M. Pöttgen C, et al. Among authors: eberhardt w. Clin Cancer Res. 2006 Jan 1;12(1):97-106. doi: 10.1158/1078-0432.CCR-05-0510. Clin Cancer Res. 2006. PMID: 16397030 Free article.
Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer.
Pöttgen C, Gauler T, Bellendorf A, Guberina M, Bockisch A, Schwenzer N, Heinzelmann F, Cordes S, Schuler MH, Welter S, Stamatis G, Friedel G, Darwiche K, Jöckel KH, Eberhardt W, Stuschke M. Pöttgen C, et al. Among authors: eberhardt w. J Clin Oncol. 2016 Jul 20;34(21):2526-33. doi: 10.1200/JCO.2015.65.5167. Epub 2016 May 31. J Clin Oncol. 2016. PMID: 27247220 Clinical Trial.
Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial.
Guberina M, Eberhardt W, Stuschke M, Gauler T, Aigner C, Schuler M, Stamatis G, Theegarten D, Jentzen W, Herrmann K, Pöttgen C. Guberina M, et al. Among authors: eberhardt w. Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1439-1447. doi: 10.1007/s00259-019-4270-x. Epub 2019 Feb 1. Eur J Nucl Med Mol Imaging. 2019. PMID: 30710323 Clinical Trial.
Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors.
Guberina M, Guberina N, Pöttgen C, Gauler T, Richlitzki C, Metzenmacher M, Wiesweg M, Plönes T, Forsting M, Wetter A, Herrmann K, Hautzel H, Darwiche K, Theegarten D, Aigner C, Schuler M, Stuschke M, Eberhardt WE. Guberina M, et al. Immunotherapy. 2022 Aug;14(12):927-944. doi: 10.2217/imt-2021-0341. Epub 2022 Jul 13. Immunotherapy. 2022. PMID: 35822656 Free article. Clinical Trial.
Combined modality therapy in NSCLC.
Eberhardt W, Bildat S, Korfee S. Eberhardt W, et al. Ann Oncol. 2000;11 Suppl 3:85-95. doi: 10.1093/annonc/11.suppl_3.85. Ann Oncol. 2000. PMID: 11079124 Free article. Review.
Prophylactic cranial irradiation in lung cancer.
Pöttgen C, Eberhardt W, Stuschke M. Pöttgen C, et al. Among authors: eberhardt w. Curr Treat Options Oncol. 2004 Feb;5(1):43-50. doi: 10.1007/s11864-004-0005-7. Curr Treat Options Oncol. 2004. PMID: 14697156 Review.
453 results